Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines
Our Lead Product Candidate
STS101
Dihydroergotamine (DHE) Nasal Powder
Learn More
Clinical Trials
SUMMIT™ Trial
Currently Recruiting
Learn More
Press Releases
May 11, 2022
Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Read More
May 10, 2022
Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
Read More